Shanghai Fosun Pharmaceutical (Group) Management
Management criteria checks 1/4
Shanghai Fosun Pharmaceutical (Group)'s CEO is Yi Liu, appointed in Jun 2025, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth CN¥904.69K. The average tenure of the management team and the board of directors is 2.1 years and 2.9 years respectively.
Key information
Yi Liu
Chief executive officer
CN¥2.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.001% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Using Too Much Debt?
Mar 21
Investors Aren't Entirely Convinced By Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s (SHSE:600196) Earnings
Jan 07Does This Valuation Of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Imply Investors Are Overpaying?
Dec 18CEO
Yi Liu (50 yo)
Dr. Yi Liu is Non-Executive Director of Shanghai Henlius Biotech, Inc. from August 29, 2025. He is an Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since December 2, 2025.Mr. Liu j...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Co-Chairman | 4yrs | CN¥3.71m | 0.011% CN¥ 7.5m | |
| Executive Chairman | 1.3yrs | no data | 0.0058% CN¥ 3.9m | |
| President | less than a year | CN¥2.73m | 0.0013% CN¥ 904.7k | |
| Executive President & Chief Human Resources Officer | less than a year | CN¥2.36m | 0.0031% CN¥ 2.1m | |
| Co-President and CEO of Established Medicines Manufacturing & Supply Division | no data | CN¥3.85m | 0.0031% CN¥ 2.1m | |
| Co-President | 2.9yrs | CN¥9.86m | no data | |
| Co-President & Co-CEO of Innovative Medicines Division | 2.9yrs | CN¥10.24m | no data | |
| Senior VP & CFO | 1.3yrs | CN¥2.64m | 0.0013% CN¥ 843.9k | |
| VP & GM of Legal Department | no data | CN¥2.13m | 0.0016% CN¥ 1.1m | |
| Executive Director | no data | CN¥5.34m | 0.012% CN¥ 8.3m | |
| Senior Vice President | 5.2yrs | CN¥2.51m | 0.0031% CN¥ 2.1m | |
| Senior Vice President | 3.9yrs | CN¥1.97m | 0.00076% CN¥ 513.1k |
Experienced Management: 600196's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Co-Chairman | 4yrs | CN¥3.71m | 0.011% CN¥ 7.5m | |
| Executive Chairman | 1.3yrs | no data | 0.0058% CN¥ 3.9m | |
| President | no data | CN¥2.73m | 0.0013% CN¥ 904.7k | |
| Executive Director | 4yrs | CN¥5.34m | 0.012% CN¥ 8.3m | |
| Chief Accountant | less than a year | no data | 0.00024% CN¥ 162.0k | |
| Non-Executive Director | 20.6yrs | no data | 0.0043% CN¥ 2.9m | |
| Independent Non-executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥400.00k | no data | |
| Executive Vice Chairman | 3.3yrs | CN¥4.09m | 0.0039% CN¥ 2.6m | |
| Independent Non-Executive Director | 4.5yrs | CN¥400.00k | no data | |
| Chairman of the Supervisory Committee | 2.5yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: 600196's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/05 17:36 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 28 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Huang | BofA Global Research |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Bo Yu | China International Capital Corporation Limited |